B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8 <sup>+</sup> tumor-infiltrating lymphocytes
Gihoon You, Yangsoon Lee, Yeon-Woo Kang, Han Wook Park, Kyeongsu Park, Hyekang Kim, Young‐Min Kim, Sora Kim, Jihae Kim, Dain Moon, Hyejin Chung, Wonjun Son, Ui-jung Jung, Eun Young Park, Shinai Lee, Yong-Gyu Son, Jaehyun Eom, Jonghwa Won, Yunji Park, Jaeho Jung, Seung‐Woo Lee
Abstract
"terminally differentiated" subset, and bsAb potentiates these cells for eliminating the tumor. Furthermore, the combination of bsAb and PD-1 blockade synergistically inhibits tumor growth accompanied by further increasing terminally differentiated CD8 T cells. B7-H3×h4-1BB also shows antitumor activity in h4-1BB-expressing mice. Our data suggest that B7-H3×4-1BB is an effective and safe therapeutic agent against B7-H3-positive cancers as monotherapy and combination therapy with PD-1 blockade.